The use of pazopanib in the treatment of disseminated soft tissue sarcoma: personal experience
- Authors: Protsenko S.A.1, Teletaeva G.M1, Latipova D.K.1, Semenova A.I1, Novik A.V1, Komarov Y.I1, Dzhalilova S.A1, Malygin A.Y.1, Degtiareva E.A1
-
Affiliations:
- N.N. Petrov National Research Center of Oncology
- Issue: Vol 29, No 7 (2022)
- Pages: 53-56
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/321028
- DOI: https://doi.org/10.18565/pharmateca.2022.7.53-56
- ID: 321028
Cite item
Abstract
Full Text
About the authors
Svetlana A. Protsenko
N.N. Petrov National Research Center of Oncology
Email: s.protsenko@list.ru
Dr. Sci. (Med.), Prof., Head of the Department of Chemotherapy and Innovative Technologies St. Petersburg, Russia
G. M Teletaeva
N.N. Petrov National Research Center of OncologySt. Petersburg, Russia
D. Kh Latipova
N.N. Petrov National Research Center of OncologySt. Petersburg, Russia
A. I Semenova
N.N. Petrov National Research Center of OncologySt. Petersburg, Russia
A. V Novik
N.N. Petrov National Research Center of OncologySt. Petersburg, Russia
Yu. I Komarov
N.N. Petrov National Research Center of OncologySt. Petersburg, Russia
Sh. A Dzhalilova
N.N. Petrov National Research Center of OncologySt. Petersburg, Russia
A. Yu Malygin
N.N. Petrov National Research Center of OncologySt. Petersburg, Russia
E. A Degtiareva
N.N. Petrov National Research Center of OncologySt. Petersburg, Russia
References
- Каприн А.Д., Старинский В.В., Петрова ГВ. Состояние онкологической помощи населению России в 2017 году. М., 2018. 236 с.
- Hoang N.T., Acevedo L.A., Mann M.J., Tolani B. A review of soft-tissue sarcomas: translation of biological advances into treatment measures. Cancer Manag Res. 2018;10:1089-114. doi: 10.2147/CMAR.S159641.
- Seetharam M., Kolla K.R., Chawla S.P Metastatic Soft Tissue Sarcomas: A Review of Treatments and New Pharmacotherapies. Clin Oncol. 2018;3:1426.
- Frezza A.M., Stacchiotti S., Gronchi A. Systemic treatment in advanced soft tissue sarcoma: what is standard, what is new. BMC Med. 2017;15(1):109. doi: 10.1186/s12916-017-0872-y.
- Miyamoto S., Kakutani S., Sato Y, et al. Drug review: Pazopanib. Jpn J Clin Oncol. 2018;48(6):503-13. doi: 10.1093/jjco/hyy053.
- Lee A.T.J., Jones R.L., Huang P.H. Pazopanib in advanced soft tissue sarcomas. Signal Transduct Target Ther. 2019;17;4:16. doi: 10.1038/s41392-019-0049-6.
- FDA approves Votrient for advanced soft tissue sarcoma. URL: https://www.drugs.com/newdrugs/fda-approves-votrient-advanced-soft-tissue-sarcoma-3199.html
- Podar K., Tonon G., Sattler M., et al. The molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proc Natl Acad Sci U S A. 2006;103(51):19478-83. doi: 10.1073/pnas.0609329103.
- Glade Bender J.L., Lee A., Reid J.M., et al. Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a children's oncology group phase I consortium report. J Clin Oncol. 2013;31(24):3034-43. doi: 10.1200/JCO.2012.47.0914.
- Sleijfer S., Ray-Coquard I., Papai Z., et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol. 2009;27(19):3126-32. doi: 10.1200/JCO.2008.21.3223.
- Van der Graaf W.T., Blay J.Y, Chawla S.P, et al. EORTC Soft Tissue and Bone Sarcoma Group; PALETTE study group. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379(9829):1879-86. doi: 10.1016/S0140-6736(12)60651-5.